593427 Disclosed is the use of an S1P receptor modulator or agonist compound 1-{ 4-[1-(4-cyclohexyl-3-trifluoromethyl-benzyloxyimino)-ethyl]-2-ethyl-benzyl} -azetidine-3-carboxylic acid (Compound A), a salt, a pharmacologically acceptable salt thereof or prodrug thereof, wherein said prodrug is defined as a compound that is transformed to the compound of formula la by hydrolysis, in the manufacture of a medicament for the treatment of an autoimmune condition in a patient, whereby the medicament is adapted to provide said S1P receptor modulator or agonist at a dosage lower than the standard daily dosage of said S1P receptor modulator or agonist during an initial period of treatment and then at an increased dosage, up to the standard daily dosage of said S1P receptor agonist.
